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The bovine and human respiratory syncytial viruses cause severe lower respiratory tract infections. Effective
vaccines against the respiratory syncytial viruses have been lacking since vaccine failures in the 1960s and
1970s. In this report, we describe a bovine respiratory syncytial virus (bRSV) challenge model in which both
classical bRSV respiratory infection and vaccine-enhanced immune pathology were reproduced. The classical,
formalin-inactivated (FI) bRSV vaccine that has been associated with vaccine failure was efficient in inducing
high antibody titers and reducing viral loads but also primed calves for a far more serious enhanced
respiratory disease after a bRSV challenge, thereby mimicking the enhanced clinical situation in FI human
RSV (hRSV)-immunized and hRSV-infected infants in the 1960s. We show that immunization with FI-bRSV
mainly primes a Th2-like inflammatory response that is characterized by a significant eosinophilic influx in the
bronchial alveolar lung fluid and lung tissues and high levels of immunoglobulin E serum antibodies. The
current model may be useful in the evaluation of new bRSV candidate vaccines for potency and safety.
The paramyxovirus bovine respiratory syncytial virus
(bRSV) is, like its human counterpart human RSV (hRSV), a
major cause of respiratory disease (23). Primary bRSV infec-
tion can result in severe lower respiratory tract disease in
susceptible cattle, although asymptomatic infections also oc-
cur. The virus causes an acute interstitial pneumonia with
alveolitis and bronchiololitis, especially in calves and yearlings
(24).
bRSV causes a range of clinical symptoms. Mild respiratory
disease is characterized by coughing, serous or mucopurulent
nasal discharge, slight to moderately increased respiratory
rates (RRs), and abnormal breath sounds. Tachypnea, harsh
lung sounds, and profound coughing characterize moderately
affected calves. The most severely affected calves may be dys-
pneic and may have subpleural and interstitial emphysema.
Emphysematous bullae may be present between lung lobules.
Generalized symptoms range from a slightly elevated rectal
temperature, mild depression, and anorexia to a high fever,
deep depression, and coma (2, 4, 14).
Vaccine development against hRSV and bRSV has been
hampered by the dramatic hRSV vaccine failure in the 1960s:
vaccination with formalin-inactivated (FI), alum-adjuvanted vi-
rus predisposed children to a far more serious, and sometimes
lethal, form of RSV infection (13). Subsequently, it was found
in the 1970s that a similarly inactivated bRSV vaccine could
induce strikingly similar immunopathology in bRSV-infected
calves (28). In fact, some inactivated veterinary vaccines were
withdrawn from the market after safety problems were discov-
ered (R. S. Schrijver, personal communication).
Studies with murine models of hRSV have demonstrated
that alum-adjuvanted FI-hRSV is a strong inducer of Th2 cells,
which proved to be the key mediators of immunological hy-
persensitivity reactions (20). In fact, immunopathogenesis in
BALB/c mice can be attributed completely to an oligoclonal
response of interleukin-5 (IL-5)-producing CD4 T cells that
are specific for the viral attachment protein (G) (26). On the
basis of these results, it is evident that further vaccine devel-
opment depends on a better understanding of the immune
mechanisms of this enhanced disease and that these parame-
ters are defined in models that allow evaluation of the safety of
candidate RSV vaccines, such as the bRSV model.
Experimental bRSV infection resulting in severe respiratory
disease in cattle has been described in only a few reports (3, 5,
6). However, a potential drawback of these studies is that it was
unclear in these studies whether other pathogenic microorgan-
isms might also have been involved in pathogenesis. For in-
stance, severe respiratory disease after bRSV infection was
reported by Ciszewski et al. (6), but the calves used were not
specific pathogen free (SPF) and pathogenic microorganisms
were in fact cultured from several animals in the experiment.
Evidently, for further study of the (immuno)pathogenesis of
bRSV infection and for evaluation of vaccine safety and effi-
cacy, development of a bRSV infection model is urgently
needed. In the present study, we have developed such a bRSV
challenge model. The impact of prior vaccination with FI or
live virus on the outcome of subsequent bRSV infection was
analyzed by using a panel of clinical and cellular parameters.
MATERIALS AND METHODS
Vaccine preparation. bRSV, strain Lelystad, sixth passage, was grown in Ear-
le’s minimal essential medium (MEM; GIBCO) supplemented with 10% fetal
bovine serum (FBS) and 0.5% antibiotic cocktail (ABC) on embryonic bovine
trachea (EBTr) cells to a titer of 105.5 50% tissue culture infective doses
(TCID50) per ml and harvested after 7 days. Supernatant (440 ml in total) was
centrifuged (15 min, 1,000  g) to remove cellular debris. The virus preparation
was inactivated by addition of a 37% formaldehyde solution (1:4,000 at 37°C,
72 h), followed by ultracentrifugation (Beckman SW28, 110,000  g, 60 min,
* Corresponding author. Mailing address: ID-Lelystad, P.O. Box 65,
NL-8200 AB Lelystad, The Netherlands. Phone: 31 (0) 320 238220.
Fax: 31 (0) 320 238225. E-mail: adriaan.antonis@wur.nl.
12067
 at LAN
D
BO
UW
UNIVERSITEIT on January 23, 2008 
jvi.asm.org
D
ow
nloaded from
 
4°C). The virus pellet was resuspended in phosphate-buffered saline (PBS) and
adjusted to a protein concentration of 0.75 mg/ml. A vaccine dose was prepared
by mixing FI-bRSV (1:1) with 2% Al(OH)3 and incubating it for 20 min at room
temperature.
Study design. Three groups of six SPF calves obtained by caesarean section,
deprived of colostrum, and reared in isolation were housed in separate isolation
rooms. The calves were free of bovine viral diarrhea virus (BVDV), as shown by
BVDV antigen enzyme-linked immunosorbent assay (ELISA) (SERELISA
BVD/MD/BD Ag; SYNBIOTICS EUROPE). After the calves were found to be
free of BVDV, they were loose housed in isolation units in groups of three.
Starting at an age of 6 weeks, all of the calves received two intramuscular
immunizations, with a 3-week interval, with either PBS, FI-bRSV adsorbed to
Al(OH)3, or live bRSV (strain Lelystad, 104.3 TCID50/ml).
All calves were challenged approximately 5 months after the first immuniza-
tion. bRSV field strain Odijk was used to prepare the challenge virus stock (25).
This strain was obtained during an outbreak of acute respiratory disease in a herd
of 3- to 5-month-old calves in December 1991 in Odijk, The Netherlands (25),
and has never been passaged on cell culture. The virus stock contained 103.9
TCID50 of bRSV per ml and was found to be free of bacteria, mycoplasmas,
bVDV, bovine herpesvirus 1, and parainfluenza 3 virus. For the challenge, all
calves were inoculated intranasally with a 2-ml bRSV challenge inoculum with an
air jet nebulizer and a jet stream of 0.2 mm, producing 10% droplets 26 m in
section, 50% droplets 50 m in section, and 90% droplets 99 m in section.
Bronchoalveolar lung fluid (BALF), heparinized blood samples, and nasal swabs
were obtained from all calves at 3 days prior to challenge and at 1, 4, 7, and 9 days
after challenge. All calves were bled weekly and 3 days before challenge and daily
thereafter for serology. All animal experiments were conducted in accordance
with the Act on Experimental Animals of The Netherlands regulated by the
Ethical Review Committee of ID-Lelystad.
Clinical examinations. Calves were clinically examined once a day before
challenge (from day 3 to day 0, the day of challenge infection) and then twice
a day after challenge (from day 0 until day 9 postinfection). Calves were exam-
ined for signs of respiratory disease, ocular and nasal discharge, coughing,
breathing, and lung sounds. Rectal temperatures and RRs were recorded. The
mean of the prechallenge clinical scores was used as a baseline value (100%).
Half-daily scores were expressed as a percentage of this baseline. Standardization
was obtained by having all examinations performed by the same veterinarian.
The severity of the clinical disease was expressed by allocating a weighting factor
for each observation (Table 1).
Bronchoalveolar lavages. BALF samples were obtained as described by
Fogarty et al. (8). Approximately 100 ml of BALF was obtained from each calf
after instillation of approximately 120 ml of PBS. BALF samples were centri-
fuged (200  g, 10 min, 4°C). Lavage cells were resuspended in fluorescence-
activated cell sorter buffer (PBS containing 25% FBS, 0.5% bovine serum albu-
min, and 0.01% Na azide), counted, further diluted to 5 106 viable cells per ml,
and used for further analysis. Droplets of resuspended cells were put on slides
and air dried. A total of 100 cells were counted (Hema-Tek slide stainer), and the
lymphocytes, monocytes, and neutrophils (mature and immature) were differen-
tiated on the basis of morphology. Viral antigen was visualized by staining
acetone-fixed cells with fluorescein isothiocyanate-conjugated monoclonal anti-
bodies (MAbs) directed against the F protein of bRSV (30 min at 37°C). BALF
cell supernatants were stored at 70°C for virus isolation, virus titration, and
PCR analyses.
Virological examination. Lavage fluid samples were centrifuged (200  g, 10
min, 4°C), and supernatant was stored at 70°C until virus isolation was done.
Virus isolations were performed in quadruplicate on EBTr cells as described
previously (25).
Viral RNA was isolated with a viral RNA isolation kit (Qiagen, Valencia,
Calif.). Reverse transcription (RT)-PCR to detect viral RNA was performed as
described by Kuno (16). Briefly, an RT-PCR mixture was prepared that con-
tained 0.5 U of RAV-2 polymerase (Amersham, Pharmacia Biotech, Roosend-
aal, The Netherlands), 1 U of Tth polymerase (Roche), 1 PCR buffer, 10 U of
RNAguard (Amersham), primers, and a 3-l RNA sample. The primers de-
signed for bRSV-N and bRSV-P were N 5 (GTTTAAACCATGGCTCTYAG
CAAGGTC), N 3 (CARTTCCACATCATTRTCTTT), P 5 (GAAATTTCCA
TGGAAAAATTTGCACCTG), and P 3 (GAAATCTTCAAGTGATAGATC
ATTG) (Y  C/T, R  A/G; degenerate because the Odijk sequence was
unknown). Water was added to make the total volume 50 l. RNA was reverse
transcribed at 50°C for 45 min, followed by 12 cycles of touchdown PCR (94°C
for 1 min; 40 to 34°C in 0.5°C increments for 1 min; 72°C for 2 min) and 30 cycles
of 94°C for 1 min, 45°C for 1 min, and 72°C for 2 min. Positive controls included
plasmids containing the bRSV strain Odijk N and P genes, as well as cDNA
prepared from bRSV strain Lelystad-infected cells. The N PCR generated a
1.1-kb product, and the P PCR generated a 0.7-kb product.
TABLE 1. Weighting factors for each clinical observationa
Parameter
Clinical sign(s) of respiratory disease at rectal temp of:
39.5°C 39.5–40.5°C 40.5°C
Ocular discharge or runny eyes None Serous or mucous Purulent or hemorragic
Nasal discharge None Serous or mucous Purulent
Coughing None Spontaneous Spontaneous and productive
RR (breaths/min) 60 60–100 100
Respiratory distress None Dyspnea
Costoabdominal Exaggerated intercostal and/
or abdominal effort
Regular breathing Irregular breathing
Respiratory noise None Abnormal or intense
respiratory sound (stridor)
Trachea sensitivity No induced cough after
moderate pressure
on trachea
Induced cough after moderate
pressure on trachea at one
particular place
Induced cough after moderate pressure
on trachea on more than one place
Lung auscultation No abnormalities Abnormal left or right lungs Abnormal both right and left lungs
Increased intensity Vesicular lung sounds
Scoringb 0 1 2
a The severity of the clinical disease was expressed by allocating a weighting factor (0, 1, or 2) for each mentioned observation (first column). For example: if the
rectal temperature is 39°C, the weighting factor is 0; if the rectal temperature is 39°C but 40.5°C, the weighting factor is 1; if the rectal temperature is 40.5°C,
the weighting factor is 2.
b Scoring values per observed observation. The total score was calculated by editing the weighting factors for each observation.
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Lung tissue samples were stored at 70°C until virus isolation was performed.
Tissues were homogenized in a mortar with sterile sea sand (Merck) in 5 ml of
Dulbecco’s MEM supplemented with 2% ABC and 5% FBS (PAN, 1302-
P221701; Biotech GmbH). The tissue suspensions were centrifuged for 10 min at
2,000  g, and the supernatant was collected. Virus isolation was performed on
24-well tissue culture plates. Each well contained a 200-l tissue suspension and
2 ml of an EBTr cell suspension (	 60,000 cells) in Earle’s MEM supplemented
with 10% FBS and 0.5% ABC. After 7 days of incubation at 37°C in 5% CO2, an
immunoperoxidase monolayer assay for bRSV was performed (25).
Humoral immune response. A double-antibody sandwich (DAS) ELISA, as
described by Westenbrink et al. (30), was used to determine bRSV-specific IgG
antibody titers. This ELISA detects antibodies directed against the fusion protein
of bRSV (F-ELISA, Ceditest ELISA for bRSV-Ab; Cedi Diagnostics, Lelystad,
The Netherlands).
A blocking G peptide ELISA, as described by Langedijk et al. (17), was used
to determine bRSV G-specific antibody titers and is based on blocking of the
binding of a bRSV G-specific MAb (MAb 20) with the coated peptide by
peptide-specific antibodies that may be present in the serum.
Neutralizing antibodies were determined in a virus neutralization assay
(VNA). VNAs were carried out as previously described (17).
A sandwich ELISA, as described by Kooyman et al. (15), was used to detect
total serum IgE responses. The value of the blank (PBS-GT) was set at 0. The
corrected optical density (OD) value of the undiluted standard serum was set at
100%. On the basis of this standard, the OD values of the test sera were
transformed to percentages, similar to the arbitrary units described by Kooyman
et al. (15).
Haptoglobin assays. Serum haptoglobin was determined (on days postimmu-
nization [dpi] 139 and 146 and daily from dpi 146 to 156) with a haptoglobin assay
from Tridelta Ltd. that is based on the preservation of hemoglobin peroxidase
activity by haptoglobin in the serum samples. Haptoglobin concentrations were
read from a standard curve.
Postmortem. Calves were anaesthetized with a pentobarbital overdose and
euthanized by exsanguination. The lungs were immediately removed, and dorsal
and ventral photographs were taken, from which the extent of macroscopic
lesions (consolidated lung areas) was rated as a percentage of the lung tissue
area. The extent of consolidated lung tissue was scored on a scale of 0 to 5 as
described by Viuff et al. (27) and used as an indication of the pneumonic lung
tissue surface area.
Necropsy samples of 10 predetermined sites were stored in 10% neutral
buffered formalin or snap-frozen in liquid nitrogen and/or frozen at 70°C.
Formalinized samples were embedded in paraffin, sectioned at 5 m, and stained
with hematoxylin and eosin for histologic examination. Snap-frozen samples
were examined for the presence of bRSV by immunohistochemistry. Long tissue
samples stored at 70°C were also used for virus isolation.
Statistical analysis. For statistical analyses, the average temperature, the av-
erage respiratory scores, and the average clinical scores of the calves before
challenge (morning measurements on dpi 143, 144, 145, and 146) were taken as
the reference (baseline) values. For each calf, the severity of the clinical symp-
toms was expressed as the area under the curve (AUC) for dpi 146 to 155 of the
experiment. Significance of correlation was calculated with the Kruskal-Wallis
nonparametric test and the Wilcoxon-Mann-Whitney test. Correlations and dif-
ferences were considered significant when P was 0.05.
RESULTS
Development of a bRSV infection model. The primary aim of
our study was to evaluate the (immuno)pathogenesis of bRSV
infection after prior immunization with an FI-bRSV vaccine.
Therefore, it was essential to first set up a bRSV vaccination-
challenge model. To achieve this, we used the bRSV field
strain Odijk. We first sought to establish infection conditions
that would produce clinical symptoms. After optimizing the
inoculation method, we found that intranasal inoculation with
an air jet nebulizer (104.2 TCID50) consistently resulted in
productive bRSV infections and clinical symptoms (data not
shown).
bRSV infection after vaccination with L-bRSV or FI-bRSV.
To assess the impact and efficacy of prior immunization with
live attenuated bRSV (L-bRSV) or FI-bRSV, SPF calves were
subjected to three different immunization regimens. Animals
were immunized with FI-bRSV or L-bRSV or received a mock
immunization with PBS. Humoral immune responses after vac-
cination were measured with commercially available F-ELISA
kits, a G peptide ELISA, and the virus-neutralizing activity was
tested in a neutralization assay. As expected, we found that
none of the mock-immunized calves had bRSV-specific anti-
bodies before inoculation. Immunization with either FI-bRSV
or L-bRSV resulted in seroconversion in all animals. Figure 1
shows the average bRSV antibody titers for each group of
calves. The first animal to test positive in the F-ELISA had
received the FI-bRSV vaccine. F-specific antibodies were de-
tected at 20 dpi. Three weeks later, all L-bRSV- and FI-bRSV-
immunized calves were positive in the F-ELISA. Interestingly,
a significantly greater antibody response (P  0.0022) was
observed in the FI-bRSV-immunized group. In contrast, the
neutralizing antibody response was stronger in the L-bRSV-
immunized group: Neutralizing antibodies were detected in
three out of six FI-bRSV-immunized calves from dpi 41 on-
ward, whereas all L-bRSV-immunized calves had neutralizing
antibody responses starting from dpi 20 (Fig. 1).
All calves were challenged at dpi 146 by intranasal inocula-
tion of 104.2 TCID50 of bRSV strain Odijk. The kinetics of viral
replication in lung washes was analyzed by virus isolation and
by RT-PCR. Unexpectedly, bRSV was detected by virus isola-
tion in only two of the animals (animals 5539 and 5550, mock
immunized and L-bRSV immunized, respectively) on days post
challenge infection (dpci) 4 and 7, respectively. Next, the pres-
ence of viral RNA was measured by RT-PCR. Viral RNA was
detected in BALF samples of four (out of six) calves at dpci 4
and in those of all six PBS-immunized calves at dpci 7. No viral
RNA was detected in BALF samples from any of the FI-
bRSV-immunized calves, whereas a weak RT-PCR signal was
detected at dpci 7 in one L-bRSV-immunized animal (data not
shown). Thus, both immunization protocols resulted in
strongly decreased viral loads after challenge. Moreover, all
FI-bRSV- and L-bRSV-immunized calves seroconverted in the
F-ELISA, G-ELISA, and VNA after challenge. Interestingly,
elevated levels of total IgE were detected in serum samples of
all FI-bRSV-immunized calves at dpci 9 (Fig. 1D). None of the
other animals showed any IgE responses.
In conclusion, both vaccines appear to be highly effective on
the basis of the reduced viral loads and induction of and/or
increases in (neutralizing) antibodies after challenge.
Clinical symptoms after challenge of FI-bRSV- or L-bRSV-
immunized or mock-immunized animals. The clinical symp-
toms after challenge were expressed as the AUC. AUC values
were calculated for 9 dpci. The parameters that were included
in the AUC calculation were increased RR, increased body
temperature, nasal discharge, coughing, sensitivity of the lar-
ynx and/or trachea, abnormal breathing, and lung sounds. In-
terestingly, clinical signs were first observed in the FI-bRSV-
immunized group. Following this trend, we found the greatest
increases in clinical scores after bRSV challenge administra-
tion in the FI-bRSV-immunized group (Fig. 2). Whereas some
of the FI-bRSV-immunized calves presented severe clinical
signs as early as 2 days after the challenge administration
(200% compared to the baseline), calves immunized with
either L-bRSV or PBS displayed clinical signs no earlier than
5 days after challenge administration. More pronounced clin-
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ical signs were observed in the PBS-immunized group than in
the L-bRSV-immunized group (Fig. 2). Differences in the av-
erage AUC values of the three different groups were significant
(P  0.0041). Compared to the AUC values of calves immu-
nized with L-bRSV, both the PBS and FI-bRSV-immunized
animals showed significantly more severe clinical symptoms
(two-sided P values of 0.0216 and 0.0087, respectively, with the
Wilcoxon-Mann-Whitney test).
Our assessment of clinical symptoms was confirmed by the
analysis of acute-phase responses (haptoglobin). Acute-phase
responses were detected, and they peaked around 8 to 9 days
after inoculation of bRSV (Fig. 3). The AUC was determined
per calf and compared within groups. The mock-immunized
group showed a significantly more severe response (P 
0.0476) than the L-bRSV-immunized group. The magnitude of
the haptoglobin response correlated well with the severity of
clinical signs and with the extent of lung consolidation in the
PBS- and L-bRSV-immunized groups.
Thus, on the basis of clinical appearances, we have been able
to model severe bRSV infection and, importantly, the en-
hanced disease after prior immunization with FI-bRSV. It is
striking that enhanced disease in the FI-bRSV-vaccinated
group coincided with a very strong reduction of viral loads
compared to the PBS-immunized control group.
Cellular immune responses in the lungs. Respiratory infec-
tion is usually accompanied by an influx of lymphocytes and
granulocytes into the lungs (Fig. 4). To obtain a better insight
into the nature of the cell populations migrating into the in-
fected lung, we performed phenotypic analyses of cells from
BALF samples. BALF samples were collected at different time
points before and after a bRSV challenge. Analysis of these
samples revealed a strong eosinophil infiltration in FI-bRSV-
immunized animals, starting at day 1 after challenge adminis-
tration (Table 2). Four out of six FI-bRSV-immunized calves
showed an eosinophilic infiltration (7% 	 10%) at day 4 after
challenge administration. Eosinophil infiltration was observed
in all calves at days 7 (19% 	 13%) and 9 (28% 	 19%) after
challenge. The influx of eosinophils was slower in the L-bRSV-
immunized group: only two BALF cell samples showed an
eosinophilic infiltration at 7 days after challenge administra-
tion (5%	 8%), and all animals showed eosinophil infiltration
by day 9 after challenge administration (10% 	 7%). The
eosinophilic infiltration observed at 7 days after the challenge
infection was significantly greater (P 0.0346) in the FI-bRSV
group. No eosinophil infiltration was observed in the PBS-
immunized group.
Pathology. All animals were euthanized at dpci 9 to allow a
detailed analysis of virus- and/or immune response-induced
FIG. 1. Humoral immune responses. Average bRSV antibody titers, with standard deviations (A, B, and C), measured at 3-week intervals (dpi
0, 20, 41, 69, 83, 104, and 125), on the day of challenge administration (dpi 146), and at the end of the experiment (dpi 156). PBS group (), six
mock-immunized calves; FI-bRSV group (), six calves immunized with FI bRSV; L-bRSV group (Œ), six calves immunized with live bRSV.
(D) IgE antibody responses detected in the IgE DAS ELISA. Corrected OD values were transformed to percentages of a standard positive serum.
Only FI-bRSV-immunized calves were found to be IgE positive. Each line represents a calf immunized with FI-bRSV vaccine. VN, virus
neutralizing.
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pathology. At necropsy, the percentage of abnormal lung sur-
face area ranged from 0.2 to 12.3% within the entire group of
18 animals. Mean percentages (	 the standard error of the
mean) in the PBS-, FI-bRSV-, and L-bRSV-immunized groups
were 8.2% 	 2.6%, 3.6% 	 2.1%, and 0.8% 	 0.7%, respec-
tively. When extended, consolidated lung tissue areas were
scored as described by Viuff et al. (27), five out of six PBS-
immunized calves and one FI-bRSV-immunized calf were
scored 2 (5 to 15% consolidated lung tissue), whereas all of the
others were scored 0 or 1. Differences between the PBS-im-
munized group and both of the other groups were significant
(one-sided P values of 0.0390 for the PBS group versus the
FI-bRSV group and 0.0076 for the PBS group versus the L-
bRSV group).
Calves of all three groups had developed multifocal bron-
chointerstitial pneumonia, often with characteristic multinu-
cleated syncytial cells, a marked proliferation of bronchiolar
epithelium, alveolar epithelialization, alveolar edema, and hy-
aline membrane formation. The lumina of many bronchioles
were narrow and were often filled with secretion. The super-
ficial bronchial epithelial cells were swollen. In the bronchiolar
walls, a variably dense lymphocytic infiltrate was observed.
Lymphocytic aggregates and follicles were visible, especially in
the calves that were immunized with PBS. The lung paren-
chyma showed atelectasis next to parts with alveolar emphy-
sema.
The pathology data confirmed our findings on eosinophilic
infiltrations in the lungs. In the calves immunized with FI-
FIG. 2. Clinical observations. Average clinical scores per group, in
percentages (with standard deviations) with regard to the baseline,
determined twice daily (AM and PM) from the time of challenge (dpi
146) until the end of the study (dpi 155). PBS group, six mock-immu-
nized calves; FI-bRSV group, six calves immunized with FI bRSV
vaccine; L-bRSV group, six calves immunized with L-bRSV vaccine.
FIG. 3. Haptoglobin analyses. Acute-phase responses were de-
tected, and they peaked around 8 to 9 dpci. The AUC was determined
per calf, and values were compared within groups. The mock-immu-
nized group showed a significantly more severe response (P  0.0476)
than the L-bRSV-immunized group. The magnitude of the haptoglo-
bin response correlated well with the severity of clinical signs and with
the extent of lung consolidation in the PBS- and L-bRSV-immunized
groups.
FIG. 4. Total numbers of cells recovered from BALF samples (y
axis) on particular days post challenge infection (x axis) per group.
Significantly more bronchoalveolar cells were recovered from FI-
bRSV-immunized calves (P  0.0152) and L-bRSV-immunized calves
(P  0.0043) than from mock-immunized calves.
TABLE 2. Total number of cells recovered in BALF samples and
percentages of eosinophilic granulocytes (EO) before and after
viral challenge
Group
No. of bronchoalveolar cells (104/ml); %
eosinophilic granules at:
3 dpci 1 dpci 4 dpci 7 dpci 9 dpci
Mock immunized 13, 0 5, 0 48, 0 49, 0 11, 0
24, 0 29, 0 13, 0 39, 0 56, 0
28, 0 31, 0 32, 0 26, 0 43, 0
14, 0 27, 0 44, 0 37, 0 53, 0
17, 0 36, 0 29, 0 48, 0 58, 0
23, 0 30, 0 23, 0 44, 0 60, 0
FI-bRSV immunized 13, 0 28, 1 49, 6 49, 18 36, 18
6, 0 41, 0 60, 27 31, 22 74, 54
13, 0 29, 0 53, 7 38, 5 20, 4
3, 0 52, 0 16, 3 107, 42 21, 14
12, 0 59, 0 59, 0 33, 13 37, 35
2, 0 15, 0 61, 0 67, 12 48, 40
L-bRSV immunized 11, 0 18, 0 17, 0 80, 20 41, 18
5, 0 13, 0 44, 0 54, 0 48, 5
9, 0 99, 1 31, 0 53, 8 56, 17
0, 0 40, 0 53, 0 34, 0 23, 6
5, 0 43, 0 34, 0 23, 0 37, 15
7, 0 16, 0 27, 0 31, 0 21, 1
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bRSV vaccine, we found marked eosinophilic tracheobronchi-
tis and bronchiolitis characterized by diffuse infiltration of
mainly eosinophils in the submucosa and in the interstitium
surrounding the bronchi and bronchioles. In addition, a focal-
to-diffuse eosinophilic periarteritis of the pulmonary arteries
was observed. Quantification of eosinophilic densities in the
respiratory tract showed no significant differences, although an
indication of a difference (P 0.0649) between the numbers of
eosinophils in the FI-bRSV-primed animals compared to those
in the live-bRSV-vaccinated calves was found. The highest
numbers of eosinophils were found surrounding the walls of
bronchi and bronchioles, and hardly any were found in the
alveolar tissue and alveolar lumina. The calves immunized with
PBS showed the most severe bronchointerstitial pneumonia
but had no eosinophilic infiltration in the respiratory system.
Finally, three predetermined site samples, chosen on the basis
of gross pathology findings, were tested for bRSV by immu-
noperoxidase monolayer assay. In none of the samples tested
was infectious bRSV detected.
DISCUSSION
In this report, we describe a bRSV challenge model in which
both the classical bRSV respiratory infection and vaccine-en-
hanced immune pathology were reproduced. We have ana-
lyzed the kinetics of viral replication in the lungs, the humoral
immune response, and the clinical symptoms in bRSV-infected
calves that had been immunized with either L-bRSV or FI-
bRSV or mock immunized with PBS.
One of the most striking findings in our study is the discrep-
ancy between viral loads and humoral immune responses on
the one hand and pathogenesis and clinical symptoms on the
other hand. Three different patterns of infection and subse-
quent pathogenesis can be distinguished. First, in PBS-immu-
nized and bRSV-infected animals, we have observed viral rep-
lication in the lungs and concurrent pathogenesis. In this
situation, clearance of the viral infection coincided with a rise
in (neutralizing) IgG antibody titers. Second, immunization
with L-bRSV provides protective immunity: viral RNA was
virtually undetectable, only mild clinical symptoms were ob-
served, and (neutralizing) antibody titers increased rapidly af-
ter a challenge infection. The third, and most striking, pattern
of infection was observed in the animals that had received the
FI-bRSV vaccine. Immunization with FI-bRSV resulted in
strong IgG antibody responses against F and G. Neutralizing
antibodies could also be detected, but titers were lower than
those of L-bRSV-immunized calves. Strikingly, these strong
antibody responses did not prevent the early onset of severe
clinical symptoms. Immune responses in these animals were
characterized by high IgE antibody titers accompanied by
marked eosinophilia. Preliminary data show that this IgE re-
sponse is, at least in part, bRSV specific (unpublished results).
Combined, these results are indicative of a type I hypersensi-
tivity reaction. It should be noted, however, that challenge
infection of L-bRSV-immunized calves was also associated
with eosinophilia, albeit in a milder form (Table 2). Combined,
we feel that our data are most consistent with a model in which
pathogenesis in FI-bRSV-immunized calves has an immuno-
logical basis, whereas infection of mock-immunized animals
leads to a more conventional virus-induced pathogenesis.
It is evident that accurate quantitation of clinical symptoms
was essential for the interpretation of our data. The parame-
ters that we have used include (i) the duration of fever, (ii) the
extent of consolidated lung areas, and (iii) the analysis of
acute-phase responses (haptoglobin). As shown by Heegaard
and coworkers (10), the magnitude and duration of the hap-
toglobin response correlate with the severity of clinical signs
(fever) and with the extent of lung consolidation. In our model,
fever was recorded in PBS-immunized calves for 2 to 3 days
and was associated with significant consolidated lung areas
(and lack of eosinophilia). In contrast, less extensive acute-
phase responses, shorter duration of fever, and less consoli-
dated lung areas were found in L-bRSV-immunized group
calves. Thus, viral loads, as well as clinical signs, were clearly
reduced in L-bRSV-immunized calves. The situation was rad-
ically different in FI-bRSV-immunized animals: a pronounced
acute-phase response was observed, peaking 6 to 7 days post-
challenge, and fever was found in all six calves for 1 to 5 days.
In contrast, pathological, consolidated lung areas were less
extensive than in mock-immunized calves. Thus, for the FI-
bRSV-immunized calves, we found no correlation between the
haptoglobin response, eosinophilia, and clinical signs on the
one hand and the extent of lung consolidation on the other
hand. However, it should be noted that the calculated consol-
idated red lung areas, used as an indication of the pneumonic
surface area, may not provide an accurate estimate of the total
pneumonic involvement since we found many deep parenchy-
mal lesions that did not have any surface involvement.
Our results obtained with FI-bRSV-immunized calves mimic
the enhanced clinical situation in FI-hRSV-immunized and
hRSV-infected infants, as reported by Kapikian et al. (12). So
far, enhanced pathogenesis after immunization with FI virus
has been difficult to reproduce in cattle. In one early study,
similar adverse effects could be induced in calves after immu-
nization with FI-bRSV vaccines (28), whereas West and co-
workers only reported an earlier onset and resolution of clin-
ical disease after immunization with FI-bRSV vaccine (29). In
the field, Schreiber et al. reported high mortality rates associ-
ated with bRSV infection in Belgian Blue calves in the field
previously vaccinated with (
-propiolactone-)inactivated
bRSV vaccine (22). In contrast, Mohanty et al. observed both
neutralizing antibodies and protection in calves after immuni-
zation with an FI-bRSV vaccine (18). Only Gershwin et al.
have been able to demonstrate that immunization with an FI
vaccine led to more severe clinical signs after a challenge
compared to those of nonvaccinated control calves (9). How-
ever, in contrast to the findings of Gershwin et al., we found
virus-neutralizing antibodies in FI-bRSV-immunized calves
and found indications of a deregulated T-cell response (IgE),
correlating with a hypersensitivity reaction (see below).
There has been extensive speculation on the nature of en-
hanced RSV pathogenesis after immunization (1, 19). So-
called “sub-neutralizing” antibodies were the first potential
culprits to be identified (1, 19). This hypothesis implies that the
antibodies primed by immunization are insufficiently neutral-
izing, with the predicted result of higher virus titers after chal-
lenge. Consistent with this, Polack et al. (21) found that en-
hanced pathogenesis in the mouse model of RSV infection is
associated with low neutralizing antibody titers, high viral ti-
ters, and the deposition of immune complexes. In contrast, we
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observed the opposite in our model: viral loads in FI-bRSV-
immunized animals were strongly reduced, since no viral RNA
was detected, and the FI-bRSV vaccine did induce virus-neu-
tralizing antibody titers. Thus, our data are inconsistent with a
model of enhancement that implies inadequate antibody func-
tion and an increased viral load.
The hypothesis that has attracted the most attention recently
states that immunization with FI vaccines mainly primes a
Th2-like inflammatory response (20). This vaccine-induced
Th2-biased memory response would then set the stage for the
expansion of Th2-polarized CD4 T cells and, indirectly, the
enhanced pulmonary lesions found after a subsequent chal-
lenge. The Th2 cytokines IL-4, IL-13, and IL-5 would play
major roles in this scheme. This model has received experi-
mental support from the well-studied murine RSV infection
model (11, 20, 26) and from an experimental RSV infection
model involving macaques (7). Interestingly, these aberrant
Th2-like responses are related to a hyperactive IgE response.
Our findings of significant eosinophil infiltrations in BALF
samples and high titers of IgE serum antibodies after a chal-
lenge infection in all FI-bRSV-immunized calves reflect an
underlying Th2-biased CD4 T-cell response. It is of interest
that a deregulated (Th2 biased) T-cell response has been hy-
pothesized to play a key role in airway hypersensitivity reac-
tions as asthma and airway hyperresponsiveness (11).
A deeper understanding of the role of vaccine-primed and
T-cell-mediated immune dysregulation, as reflected by IgE re-
sponses, is a prerequisite for future rational vaccine design,
and the bovine RSV infection model described in this study
could be instrumental in understanding disease augmentation.
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